

283629USOPCTSTS25
SEQUENCE LISTING

<110> Sugiyama, Haruo

<120> Method of selecting patients suitable for WT1 vaccine

<130> 664590

<140> 10/562,486

<141> 2005-12-27

<150> PCT/JP2004/009378

<151> 2004-06-25

<150> JP 2003-184436

<151> 2003-06-27

<150> JP 2004-070497

<151> 2004-03-12

<160> 22

<170> PatentIn Ver. 2.1

<210> 1

<211> 449

<212> PRT

<213> Homo sapiens

<400> 1

```

Met Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Pro
 1      5      10
Ser Leu Gly Gly Gly Gly Gly Cys Ala Leu Pro Val Ser Gly Ala Ala
      20      25      30
Gln Trp Ala Pro Val Leu Asp Phe Ala Pro Pro Gly Ala Ser Ala Tyr
      35      40      45
Gly Ser Leu Gly Gly Pro Ala Pro Pro Pro Ala Pro Pro Pro Pro
 50      55      60
Pro Pro Pro Pro His Ser Phe Ile Lys Gln Glu Pro Ser Trp Gly Gly
 65      70      75      80
Ala Glu Pro His Glu Glu Gln Cys Leu Ser Ala Phe Thr Val His Phe
      85      90      95
Ser Gly Gln Phe Thr Gly Thr Ala Gly Ala Cys Arg Tyr Gly Pro Phe
      100      105      110
Gly Pro Pro Pro Pro Ser Gln Ala Ser Ser Gly Gln Ala Arg Met Phe
      115      120      125
Pro Asn Ala Pro Tyr Leu Pro Ser Cys Leu Glu Ser Gln Pro Ala Ile
      130      135      140
Arg Asn Gln Gly Tyr Ser Thr Val Thr Phe Asp Gly Thr Pro Ser Tyr
      145      150      155      160
Gly His Thr Pro Ser His His Ala Ala Gln Phe Pro Asn His Ser Phe
      165      170      175
Lys His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu Gln Gln
      180      185      190
Tyr Ser Val Pro Pro Pro Val Tyr Gly Cys His Thr Pro Thr Asp Ser

```

195 200 205
 Cys Thr Gly Ser Gln Ala Leu Leu Leu Arg Thr Pro Tyr Ser Ser Asp
 210 215 220
 Asn Leu Tyr Gln Met Thr Ser Gln Leu Glu Cys Met Thr Trp Asn Gln
 225 230 235 240
 Met Asn Leu Gly Ala Thr Leu Lys Gly Val Ala Ala Gly Ser Ser Ser
 245 250 255
 Ser Val Lys Trp Thr Glu Gly Gln Ser Asn His Ser Thr Gly Tyr Glu
 260 265 270
 Ser Asp Asn His Thr Thr Pro Ile Leu Cys Gly Ala Gln Tyr Arg Ile
 275 280 285
 His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg Arg Val Pro
 290 295 300
 Gly Val Ala Pro Thr Leu Val Arg Ser Ala Ser Glu Thr Ser Glu Lys
 305 310 315 320
 Arg Pro Phe Met Cys Ala Tyr Pro Gly Cys Asn Lys Arg Tyr Phe Lys
 325 330 335
 Leu Ser His Leu Gln Met His Ser Arg Lys His Thr Gly Glu Lys Pro
 340 345 350
 Tyr Gln Cys Asp Phe Lys Asp Cys Glu Arg Arg Phe Ser Arg Ser Asp
 355 360 365
 Gln Leu Lys Arg His Gln Arg Arg His Thr Gly Val Lys Pro Phe Gln
 370 375 380
 Cys Lys Thr Cys Gln Arg Lys Phe Ser Arg Ser Asp His Leu Lys Thr
 385 390 395 400
 His Thr Arg Thr His Thr Gly Lys Thr Ser Glu Lys Pro Phe Ser Cys
 405 410 415
 Arg Trp Pro Ser Cys Gln Lys Lys Phe Ala Arg Ser Asp Glu Leu Val
 420 425 430
 Arg His His Asn Met His Gln Arg Asn Met Thr Lys Leu Gln Leu Ala
 435 440 445
 Leu

<210> 2

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 2

Cys Met Thr Trp Asn Gln Met Asn Leu

1

5

<210> 3

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 3

Cys Tyr Thr Trp Asn Gln Met Asn Leu
1 5

<210> 4

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 4

Arg Met Phe Pro Asn Ala Pro Tyr Leu
1 5

<210> 5

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 5

Arg Tyr Pro Ser Cys Gln Lys Lys Phe
1 5

<210> 6

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 6

Ser Tyr Thr Trp Asn Gln Met Asn Leu
1 5

<210> 7

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 7

Ala Tyr Thr Trp Asn Gln Met Asn Leu
1 5

<210> 8

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 8

Gly Tyr Thr Trp Asn Gln Met Asn Leu
1 5

<210> 9

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 9

Arg Tyr Thr Trp Asn Gln Met Asn Leu
1 5

<210> 10

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 10

Lys Tyr Thr Trp Asn Gln Met Asn Leu
1 5

<210> 11

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 11

Arg Tyr Phe Pro Asn Ala Pro Tyr Leu
1 5

<210> 12

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 12

Arg Tyr Pro Gly Val Ala Pro Thr Leu
1 5

<210> 13

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 13

Ala Tyr Leu Pro Ala Val Pro Ser Leu
 1 5

<210> 14
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Peptide

<400> 14
 Asn Tyr Met Asn Leu Gly Ala Thr Leu
 1 5

<210> 15
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Peptide

<400> 15
 Arg Val Pro Gly Val Ala Pro Thr Leu
 1 5

<210> 16
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Peptide

<400> 16
 Arg Tyr Pro Ser Ser Gln Lys Lys Phe
 1 5

<210> 17
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Peptide

<400> 17
 Arg Tyr Pro Ser Ala Gln Lys Lys Phe
 1 5

<210> 18
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Peptide

<400> 18
 Arg Tyr Pro Ser Gly Gln Lys Lys Phe
 1 5

283629US0PCTSTS25

<210> 19
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic DNA

<400> 19
 ccatgggcag ccattctatg cgctattttt ctacctccgt 40

<210> 20
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Reverse Primer

<400> 20
 ggatcctggc tcccatctca gggtgagggg cttgggcaga ccctc 45

<210> 21
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic DNA

<400> 21
 catatgatcc agcgtacccc gaaaattcag 30

<210> 22
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Reverse Primer

<400> 22
 ggatccttac atgtctcgat cccacttaac 30